皮下免疫疗法安全性：基于调查的发生率和危险因素。
Subcutaneous Immunotherapy Safety: Incidence per Surveys and Risk Factors.
机构信息
Allergy and Clinical Immunology Department, Centro Médico Docente La Trinidad and Clínica El Avila, 6a transversal Urb. Altamira, piso 8, consultorio 803, Caracas 1060, Venezuela.
Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0563, USA; Bernstein Clinical Research Center, Cincinnati, OH, USA.
出版信息
Immunol Allergy Clin North Am. 2020 Feb;40(1):25-39. doi: 10.1016/j.iac.2019.09.001.
Subcutaneous immunotherapy (SCIT) is effective for allergic rhinitis and conjunctivitis, asthma, and insect venom hypersensitivity. The risk of severe allergic reactions induced by SCIT remains low, and mild systemic reactions have recently shown a tendency to decline. However, near-fatal and fatal anaphylactic reactions may occur. Clinicians administering allergen-specific immunotherapy should receive specialized training and be aware of risk factors and preventive measures to avoid severe allergic reactions induced by SCIT.
皮下免疫疗法（SCIT）对过敏性鼻炎和结膜炎、哮喘和昆虫毒液过敏症有效。SCIT 引起严重过敏反应的风险仍然较低，且最近轻度全身性反应呈下降趋势。但是，仍可能发生接近致命和致命的过敏性反应。给予变应原特异性免疫疗法的临床医生应接受专门培训，并了解危险因素和预防措施，以避免 SCIT 引起的严重过敏反应。
Zotero 插件